Literature DB >> 25230799

Our evolving understanding of migraine with aura.

Justin M DeLange1, F Michael Cutrer.   

Abstract

Migraine aura consists of fully reversible focal neurologic symptoms that may precede or coexist with headache in a significant minority of migraine patients. Typical aura symptoms include visual, sensory, and language disturbances. The most recent International Classification of Headache Disorders, 3rd edition (beta version) has added other aura types such as brainstem localizing symptoms, lateralizing weakness, and monocular visual loss. Currently available data from animal models and functional neuroimaging in humans implicate cortical spreading depression (CSD) as the phenomenon underlying migraine aura. Ongoing study suggests that susceptibility to migraine aura and CSD may be genetically mediated. CSD appears to be a potential target for future development of migraine-specific preventive therapies.

Entities:  

Mesh:

Year:  2014        PMID: 25230799     DOI: 10.1007/s11916-014-0453-0

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  143 in total

Review 1.  Migraine and stroke: perspectives for stroke physicians.

Authors:  Tobias Kurth; Hans-Christoph Diener
Journal:  Stroke       Date:  2012-09-20       Impact factor: 7.914

2.  Altered allelic distributions of the serotonin transporter gene in migraine without aura and migraine with aura.

Authors:  A D Ogilvie; M B Russell; P Dhall; S Battersby; V Ulrich; C A Smith; G M Goodwin; A J Harmar; J Olesen
Journal:  Cephalalgia       Date:  1998-01       Impact factor: 6.292

3.  Characteristics of migraine visual aura in Southern Brazil and Northern USA.

Authors:  Luiz Paulo Queiroz; Deborah Isa Friedman; Alan Mark Rapoport; R Allan Purdy
Journal:  Cephalalgia       Date:  2011-11-24       Impact factor: 6.292

4.  Retinal migraine reappraised.

Authors:  B M Grosberg; S Solomon; D I Friedman; R B Lipton
Journal:  Cephalalgia       Date:  2006-11       Impact factor: 6.292

5.  De novo mutations in ATP1A2 and CACNA1A are frequent in early-onset sporadic hemiplegic migraine.

Authors:  F Riant; A Ducros; C Ploton; C Barbance; C Depienne; E Tournier-Lasserve
Journal:  Neurology       Date:  2010-09-14       Impact factor: 9.910

6.  A nosographic analysis of the migraine aura in a general population.

Authors:  M B Russell; J Olesen
Journal:  Brain       Date:  1996-04       Impact factor: 13.501

7.  Familial and sporadic hemiplegic migraine: diagnosis and treatment.

Authors:  Nadine Pelzer; Anine H Stam; Joost Haan; Michel D Ferrari; Gisela M Terwindt
Journal:  Curr Treat Options Neurol       Date:  2013-02       Impact factor: 3.598

8.  Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine.

Authors:  J Olesen; B Larsen; M Lauritzen
Journal:  Ann Neurol       Date:  1981-04       Impact factor: 10.422

9.  A randomized controlled trial of intranasal ketamine in migraine with prolonged aura.

Authors:  Shazia K Afridi; Nicola J Giffin; Holger Kaube; Peter J Goadsby
Journal:  Neurology       Date:  2013-01-30       Impact factor: 9.910

10.  Migraine headache is present in the aura phase: a prospective study.

Authors:  Jakob M Hansen; Richard B Lipton; David W Dodick; Stephen D Silberstein; Joel R Saper; Sheena K Aurora; Peter J Goadsby; Andrew Charles
Journal:  Neurology       Date:  2012-10-31       Impact factor: 9.910

View more
  3 in total

Review 1.  The role of visual system in migraine.

Authors:  Stefania Bianchi Marzoli; Alessandra Criscuoli
Journal:  Neurol Sci       Date:  2017-05       Impact factor: 3.307

2.  Migraine-Like Visual Auras Among Traumatized Cambodians with PTSD: Fear of Ghost Attack and Other Disasters.

Authors:  Devon E Hinton; Ria Reis; Joop de Jong
Journal:  Cult Med Psychiatry       Date:  2018-06

3.  The beneficial effect of Alpha-lipoic acid supplementation as a potential adjunct treatment in episodic migraines.

Authors:  Mahnaz Rezaei Kelishadi; Amirmansour Alavi Naeini; Fariborz Khorvash; Gholamreza Askari; Zahra Heidari
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.